Raras
Buscar doenças, sintomas, genes...
Hipertensão arterial pulmonar hereditária
ORPHA:275777CID-10 · I27.0CID-11 · BB01.0PCDT · SUSDOENÇA RARA

A Hipertensão Arterial Pulmonar Hereditária (HPAH) é um tipo de Hipertensão Arterial Pulmonar (HAP) que acontece por causa de alterações (mutações) em genes que predispõem à HAP, ou quando há casos na família. A HPAH se caracteriza por uma resistência alta nas artérias dos pulmões, o que leva à falha do lado direito do coração. É uma doença progressiva e que pode ser fatal.

Mantido por Agente Raras·Colaborar como especialista →

Introdução

O que você precisa saber de cara

📋

A Hipertensão Arterial Pulmonar Hereditária (HPAH) é um tipo de Hipertensão Arterial Pulmonar (HAP) que acontece por causa de alterações (mutações) em genes que predispõem à HAP, ou quando há casos na família. A HPAH se caracteriza por uma resistência alta nas artérias dos pulmões, o que leva à falha do lado direito do coração. É uma doença progressiva e que pode ser fatal.

Pesquisas ativas
29 ensaios
829 total registrados no ClinicalTrials.gov
Publicações científicas
184 artigos
Último publicado: 1993

Escala de raridade

CLASSIFICAÇÃO ORPHANET · BRASIL 2024
<1 / 1 000 000
Ultra-rara
<1/50k
Muito rara
1/20k
Rara
1/10k
Pouco freq.
1/5k
Incomum
1/2k
Prevalência
0.08
Europe
Início
All ages
🏥
SUS: Cobertura parcialScore: 55%
PCDT disponível7 medicamentos CEAFCID-10: I27.0
🇧🇷Dados SUS / DATASUS2024
4.560
internações/ano
R$ 9.870
custo médio/internação
ESTADOS COM MAIS INTERNAÇÕES
SPMGRJRSBA
Você se identifica com essa condição?
O Raras está aqui pra te apoiar — com ou sem diagnóstico

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Entender a doença

Do básico ao detalhe, leia no seu ritmo

Preparando trilha educativa...

Sinais e sintomas

O que aparece no corpo e com que frequência cada sintoma acontece

Partes do corpo afetadas

🫁
Pulmão
12 sintomas
❤️
Coração
11 sintomas
🩸
Sangue
2 sintomas
💪
Músculos
1 sintomas
📏
Crescimento
1 sintomas

+ 12 sintomas em outras categorias

Características mais comuns

Hipertrofia ventricular direita
Dispneia de esforço
Fibrose intimal arterial pulmonar
Pressão elevada do átrio direito
Dispneia
Insuficiência ventricular direita
39sintomas
Sem dados (39)

Os sintomas variam de pessoa para pessoa. Abaixo estão as 39 características clínicas mais associadas, ordenadas por frequência.

Hipertrofia ventricular direitaRight ventricular hypertrophy
Dispneia de esforçoExertional dyspnea
Fibrose intimal arterial pulmonarPulmonary aterial intimal fibrosis
Pressão elevada do átrio direitoElevated right atrial pressure
DispneiaDyspnea

Linha do tempo da pesquisa

Publicações por ano — veja quando o interesse científico cresceu
Anos de pesquisa1desde 2026
Total histórico184PubMed
Últimos 10 anos127publicações
Pico201721 papers
Linha do tempo
2026Hoje · 2026🧪 1991Primeiro ensaio clínico📈 2017Ano de pico
Publicações por ano (últimos 10 anos)

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Genética e causas

O que está alterado no DNA e como passa nas famílias

Genes associados

12 genes identificados com associação a esta condição. Padrão de herança: Autosomal dominant, Autosomal recessive.

CAPNS1Calpain small subunit 1Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Regulatory subunit of the calcium-regulated non-lysosomal thiol-protease which catalyzes limited proteolysis of substrates involved in cytoskeletal remodeling and signal transduction. Essential for embryonic development (By similarity)

LOCALIZAÇÃO

CytoplasmCell membrane

VIAS BIOLÓGICAS (5)
Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cellsHigh laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cellsDeregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease modelsDegradation of the extracellular matrixFormation of the cornified envelope
MECANISMO DE DOENÇA

Pulmonary hypertension, primary, 6

A form of primary pulmonary hypertension, a disease defined by plexiform lesions of proliferating endothelial cells in pulmonary arterioles. The lesions lead to elevated pulmonary arterial pression, right ventricular failure, and death. Primary pulmonary hypertension exhibits incomplete penetrance, sex bias and variable age of onset, both within and between families. PPH6 is an autosomal recessive form.

OUTRAS DOENÇAS (1)
pulmonary hypertension, primary, 6
HGNC:HGNC:1481UniProt:P04632
BMPR2Bone morphogenetic protein receptor type-2Disease-causing germline mutation(s) (loss of function) inAltamente restrito
FUNÇÃO

On ligand binding, forms a receptor complex consisting of two type II and two type I transmembrane serine/threonine kinases. Type II receptors phosphorylate and activate type I receptors which autophosphorylate, then bind and activate SMAD transcriptional regulators. Can also mediate signaling through the activation of the p38MAPK cascade (PubMed:12045205). Binds to BMP7, BMP2 and, less efficiently, BMP4. Binding is weak but enhanced by the presence of type I receptors for BMPs. Mediates inducti

LOCALIZAÇÃO

Cell membrane

VIAS BIOLÓGICAS (1)
Signaling by BMP
MECANISMO DE DOENÇA

Pulmonary hypertension, primary, 1

A rare disorder characterized by plexiform lesions of proliferating endothelial cells in pulmonary arterioles. The lesions lead to elevated pulmonary arterial pression, right ventricular failure, and death. The disease can occur from infancy throughout life and it has a mean age at onset of 36 years. Penetrance is reduced. Although familial pulmonary hypertension is rare, cases secondary to known etiologies are more common and include those associated with the appetite-suppressant drugs.

VIAS REACTOME (1)
OUTRAS DOENÇAS (6)
pulmonary hypertension, primary, 1pulmonary venoocclusive disease 1pulmonary arterial hypertensionpulmonary venoocclusive disease
HGNC:1078UniProt:Q13873
ATP13A3Polyamine-transporting ATPase 13A3Disease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

ATP-driven pump involved in endocytosis-dependent polyamine transport. Uses ATP as an energy source to transfer polyamine precursor putrescine from the endosomal compartment to the cytosol

LOCALIZAÇÃO

Recycling endosome membraneEarly endosome membraneLate endosome membrane

MECANISMO DE DOENÇA

Pulmonary hypertension, primary, 5

A form of primary pulmonary hypertension, a disease defined by plexiform lesions of proliferating endothelial cells in pulmonary arterioles. The lesions lead to elevated pulmonary arterial pression, right ventricular failure, and death. Primary pulmonary hypertension exhibits incomplete penetrance, sex bias and variable age of onset, both within and between families. PPH5 is an autosomal recessive form characterized by the onset in infancy. Death in early childhood is common.

INTERAÇÕES PROTEICAS (2)
OUTRAS DOENÇAS (2)
pulmonary hypertension, primary, 5heritable pulmonary arterial hypertension
HGNC:24113UniProt:Q9H7F0
GDF2Growth/differentiation factor 2Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Potent circulating inhibitor of angiogenesis. Signals through the type I activin receptor ACVRL1 but not other Alks. Signaling through SMAD1 in endothelial cells requires TGF-beta coreceptor endoglin/ENG

LOCALIZAÇÃO

Secreted

VIAS BIOLÓGICAS (1)
Signaling by BMP
MECANISMO DE DOENÇA

Telangiectasia, hereditary hemorrhagic, 5

A multisystemic vascular dysplasia leading to dilation of permanent blood vessels and arteriovenous malformations of skin, mucosa, and viscera. The disease is characterized by recurrent epistaxis and gastro-intestinal hemorrhage. Visceral involvement includes arteriovenous malformations of the lung, liver, and brain.

VIAS REACTOME (1)
EXPRESSÃO TECIDUAL(Tecido-específico)
Fígado
8.3 TPM
Testículo
0.1 TPM
Coração - Átrio
0.1 TPM
Brain Nucleus accumbens basal ganglia
0.0 TPM
Hipotálamo
0.0 TPM
OUTRAS DOENÇAS (3)
telangiectasia, hereditary hemorrhagic, type 5hereditary hemorrhagic telangiectasiaheritable pulmonary arterial hypertension
HGNC:4217UniProt:Q9UK05
KCNK3Potassium channel subfamily K member 3Disease-causing germline mutation(s) (loss of function) inRestrito
FUNÇÃO

K(+) channel that conducts voltage-dependent outward rectifying currents upon membrane depolarization. Voltage sensing is coupled to K(+) electrochemical gradient in an 'ion flux gating' mode where outward but not inward ion flow opens the gate (PubMed:23169818, PubMed:26919430, PubMed:32499642, PubMed:36195757, PubMed:9312005). Changes ion selectivity and becomes permeable to Na(+) ions in response to extracellular acidification. Protonation of the pH sensor His-98 stabilizes C-type inactivatio

LOCALIZAÇÃO

Cell membrane

VIAS BIOLÓGICAS (2)
Phase 4 - resting membrane potentialTWIK-releated acid-sensitive K+ channel (TASK)
MECANISMO DE DOENÇA

Pulmonary hypertension, primary, 4

A rare disorder characterized by plexiform lesions of proliferating endothelial cells in pulmonary arterioles. The lesions lead to elevated pulmonary arterial pression, right ventricular failure, and death. The disease can occur from infancy throughout life and it has a mean age at onset of 36 years. Penetrance is reduced. Although familial pulmonary hypertension is rare, cases secondary to known etiologies are more common and include those associated with the appetite-suppressant drugs.

EXPRESSÃO TECIDUAL(Ubíquo)
Glândula adrenal
248.3 TPM
Pulmão
47.2 TPM
Cérebro - Hemisfério cerebelar
21.2 TPM
Cerebelo
20.3 TPM
Artéria coronária
17.0 TPM
OUTRAS DOENÇAS (2)
pulmonary hypertension, primary, 4heritable pulmonary arterial hypertension
HGNC:6278UniProt:O14649
SOX17Transcription factor SOX-17Major susceptibility factor inAltamente restrito
FUNÇÃO

Acts as a transcription regulator that binds target promoter DNA (PubMed:33952808). Binds to the sequences 5'-AACAAT-'3 or 5'-AACAAAG-3'. Modulates transcriptional regulation via WNT3A. Inhibits Wnt signaling. Promotes degradation of activated CTNNB1. Plays a key role in the regulation of embryonic development. Required for normal development of the definitive gut endoderm. Required for normal looping of the embryonic heart tube. Plays an important role in embryonic and postnatal vascular develo

LOCALIZAÇÃO

Nucleus

VIAS BIOLÓGICAS (4)
Deactivation of the beta-catenin transactivating complexFormation of definitive endodermDevelopmental Lineage of Multipotent Pancreatic Progenitor CellsSpecification of primordial germ cells
MECANISMO DE DOENÇA

Vesicoureteral reflux 3

A disease belonging to the group of congenital anomalies of the kidney and urinary tract. It is characterized by the reflux of urine from the bladder into the ureters and sometimes into the kidneys, and is a risk factor for urinary tract infections. Primary disease results from a developmental defect of the ureterovesical junction. In combination with intrarenal reflux, the resulting inflammatory reaction may result in renal injury or scarring, also called reflux nephropathy. Extensive renal scarring impairs renal function and may predispose patients to hypertension, proteinuria, renal insufficiency and end-stage renal disease.

EXPRESSÃO TECIDUAL(Ubíquo)
Adipose Visceral Omentum
69.4 TPM
Nervo tibial
51.3 TPM
Mama
47.3 TPM
Fallopian Tube
45.6 TPM
Tecido adiposo
44.5 TPM
OUTRAS DOENÇAS (3)
vesicoureteral reflux 3heritable pulmonary arterial hypertensionfamilial vesicoureteral reflux
HGNC:18122UniProt:Q9H6I2
CAV1Caveolin-1Disease-causing germline mutation(s) inTolerante
FUNÇÃO

May act as a scaffolding protein within caveolar membranes (PubMed:11751885). Forms a stable heterooligomeric complex with CAV2 that targets to lipid rafts and drives caveolae formation. Mediates the recruitment of CAVIN proteins (CAVIN1/2/3/4) to the caveolae (PubMed:19262564). Interacts directly with G-protein alpha subunits and can functionally regulate their activity (By similarity). Involved in the costimulatory signal essential for T-cell receptor (TCR)-mediated T-cell activation. Its bind

LOCALIZAÇÃO

Golgi apparatus membraneCell membraneMembrane, caveolaMembrane raftGolgi apparatus, trans-Golgi networkCytoplasm

VIAS BIOLÓGICAS (4)
SARS-CoV-2 targets host intracellular signalling and regulatory pathwaysSARS-CoV-1 targets host intracellular signalling and regulatory pathwaysExtra-nuclear estrogen signalingBasigin interactions
MECANISMO DE DOENÇA

Lipodystrophy, congenital generalized, 3

A form of congenital generalized lipodystrophy, a metabolic disorder characterized by a near complete absence of adipose tissue, extreme insulin resistance, hypertriglyceridemia, hepatic steatosis and diabetes mellitus. CGL3 inheritance is autosomal recessive.

OUTRAS DOENÇAS (6)
pulmonary hypertension, primary, 3partial lipodystrophy, congenital cataracts, and neurodegeneration syndromecongenital generalized lipodystrophy type 3heritable pulmonary arterial hypertension
HGNC:1527UniProt:Q03135
EIF2AK4eIF-2-alpha kinase GCN2Disease-causing germline mutation(s) (loss of function) inTolerante
FUNÇÃO

Metabolic-stress sensing protein kinase that phosphorylates the alpha subunit of eukaryotic translation initiation factor 2 (EIF2S1/eIF-2-alpha) in response to low amino acid availability (PubMed:25329545, PubMed:32610081). Plays a role as an activator of the integrated stress response (ISR) required for adaptation to amino acid starvation (By similarity). EIF2S1/eIF-2-alpha phosphorylation in response to stress converts EIF2S1/eIF-2-alpha into a global protein synthesis inhibitor, leading to a

LOCALIZAÇÃO

Cytoplasm

VIAS BIOLÓGICAS (1)
Response of EIF2AK4 (GCN2) to amino acid deficiency
MECANISMO DE DOENÇA

Pulmonary venoocclusive disease 2, autosomal recessive

A disease characterized by widespread fibrous obstruction and intimal thickening of septal veins and preseptal venules, a low diffusing capacity for carbon monoxide, occult alveolar hemorrhage, and nodular ground-glass opacities, septal lines and lymph node enlargement showed by high-resolution computed tomography of the chest. It is frequently associated with pulmonary capillary dilatation and proliferation, and is a rare and devastating cause of pulmonary hypertension.

EXPRESSÃO TECIDUAL(Ubíquo)
Fibroblastos
48.7 TPM
Linfócitos
23.7 TPM
Pituitária
21.8 TPM
Nervo tibial
17.1 TPM
Útero
16.6 TPM
OUTRAS DOENÇAS (3)
pulmonary venoocclusive disease 2heritable pulmonary arterial hypertensionpulmonary venoocclusive disease
HGNC:19687UniProt:Q9P2K8
SMAD9SMAD family member 9Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Transcriptional modulator activated by BMP (bone morphogenetic proteins) type 1 receptor kinase. SMAD9 is a receptor-regulated SMAD (R-SMAD)

LOCALIZAÇÃO

CytoplasmNucleus

VIAS BIOLÓGICAS (1)
Signaling by BMP
MECANISMO DE DOENÇA

Pulmonary hypertension, primary, 2

A rare disorder characterized by plexiform lesions of proliferating endothelial cells in pulmonary arterioles. The lesions lead to elevated pulmonary arterial pression, right ventricular failure, and death. The disease can occur from infancy throughout life and it has a mean age at onset of 36 years. Penetrance is reduced. Although familial pulmonary hypertension is rare, cases secondary to known etiologies are more common and include those associated with the appetite-suppressant drugs.

VIAS REACTOME (1)
EXPRESSÃO TECIDUAL(Ubíquo)
Tireoide
50.1 TPM
Artéria tibial
41.0 TPM
Aorta
30.6 TPM
Esôfago - Muscular
27.2 TPM
Brain Spinal cord cervical c-1
19.7 TPM
OUTRAS DOENÇAS (2)
pulmonary hypertension, primary, 2heritable pulmonary arterial hypertension
HGNC:6774UniProt:O15198
TBX4T-box transcription factor TBX4Disease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Transcriptional regulator that has an essential role in the organogenesis of lungs, pelvis, and hindlimbs

LOCALIZAÇÃO

Nucleus

MECANISMO DE DOENÇA

Ischiocoxopodopatellar syndrome with or without pulmonary arterial hypertension

An autosomal dominant bone disease characterized by patellar aplasia or hypoplasia and by anomalies of the pelvis and feet, including disrupted ossification of the ischia and inferior pubic rami.

EXPRESSÃO TECIDUAL(Tecido-específico)
Pulmão
54.1 TPM
Bladder
6.1 TPM
Próstata
5.3 TPM
Artéria tibial
4.7 TPM
Testículo
2.7 TPM
OUTRAS DOENÇAS (6)
coxopodopatellar syndromeautosomal recessive ameliafamilial clubfoot due to 17q23.1q23.2 microduplicationchromosome 17q23.1-q23.2 deletion syndrome
HGNC:11603UniProt:P57082
ENGEndoglinCandidate gene tested inAltamente restrito
FUNÇÃO

Vascular endothelium glycoprotein that plays an important role in the regulation of angiogenesis (PubMed:21737454, PubMed:23300529). Required for normal structure and integrity of adult vasculature (PubMed:7894484). Regulates the migration of vascular endothelial cells (PubMed:17540773). Required for normal extraembryonic angiogenesis and for embryonic heart development (By similarity). May regulate endothelial cell shape changes in response to blood flow, which drive vascular remodeling and est

LOCALIZAÇÃO

Cell membrane

VIAS BIOLÓGICAS (1)
N-glycan trimming in the ER and Calnexin/Calreticulin cycle
MECANISMO DE DOENÇA

Telangiectasia, hereditary hemorrhagic, 1

A multisystemic vascular dysplasia leading to dilation of permanent blood vessels and arteriovenous malformations of skin, mucosa, and viscera. The disease is characterized by recurrent epistaxis and gastro-intestinal hemorrhage. Visceral involvement includes arteriovenous malformations of the lung, liver, and brain.

EXPRESSÃO TECIDUAL(Ubíquo)
Aorta
476.7 TPM
Pulmão
392.6 TPM
Ovário
380.3 TPM
Artéria coronária
376.9 TPM
Coração - Átrio
355.2 TPM
OUTRAS DOENÇAS (5)
telangiectasia, hereditary hemorrhagic, type 1generalized juvenile polyposis/juvenile polyposis colihereditary hemorrhagic telangiectasiaintracranial berry aneurysm
HGNC:3349UniProt:P17813
ACVRL1Activin receptor type-1-likeCandidate gene tested inRestrito
FUNÇÃO

Type I receptor for TGF-beta family ligands BMP9/GDF2 and BMP10 and important regulator of normal blood vessel development. On ligand binding, forms a receptor complex consisting of two type II and two type I transmembrane serine/threonine kinases. Type II receptors phosphorylate and activate type I receptors which autophosphorylate, then bind and activate SMAD transcriptional regulators. May bind activin as well

LOCALIZAÇÃO

Cell membrane

VIAS BIOLÓGICAS (1)
Signaling by BMP
MECANISMO DE DOENÇA

Telangiectasia, hereditary hemorrhagic, 2

A multisystemic vascular dysplasia leading to dilation of permanent blood vessels and arteriovenous malformations of skin, mucosa, and viscera. The disease is characterized by recurrent epistaxis and gastro-intestinal hemorrhage. Visceral involvement includes arteriovenous malformations of the lung, liver, and brain.

VIAS REACTOME (1)
OUTRAS DOENÇAS (3)
telangiectasia, hereditary hemorrhagic, type 2hereditary hemorrhagic telangiectasiaheritable pulmonary arterial hypertension
HGNC:175UniProt:P37023

Variantes genéticas (ClinVar)

741 variantes patogênicas registradas no ClinVar.

🧬 CAPNS1: NM_001749.4(CAPNS1):c.209+7C>T ()
🧬 CAPNS1: GRCh37/hg19 19q11-13.13(chr19:28271107-38637350)x1 ()
🧬 CAPNS1: GRCh37/hg19 19q13.11-13.12(chr19:35223021-36895699)x1 ()
🧬 CAPNS1: NM_001749.4(CAPNS1):c.210-2A>G ()
🧬 CAPNS1: NM_001749.4(CAPNS1):c.721+1G>A ()
Ver todas no ClinVar

Classificação de variantes (ClinVar)

Distribuição de 1 variantes classificadas pelo ClinVar.

1
VUS (100.0%)
VARIANTES MAIS SIGNIFICATIVAS
ACVRL1: NM_000020.3(ACVRL1):c.721C>T (p.Arg241Trp) [Uncertain significance]

Vias biológicas (Reactome)

47 vias biológicas associadas aos genes desta condição.

Degradation of the extracellular matrix Formation of the cornified envelope Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells Signaling by BMP TWIK-releated acid-sensitive K+ channel (TASK) Phase 4 - resting membrane potential Deactivation of the beta-catenin transactivating complex Formation of definitive endoderm Specification of primordial germ cells Developmental Lineage of Multipotent Pancreatic Progenitor Cells Triglyceride catabolism eNOS activation NOSTRIN mediated eNOS trafficking Thyroxine biosynthesis Basigin interactions Disassembly of the destruction complex and recruitment of AXIN to the membrane VEGFR2 mediated vascular permeability RHOA GTPase cycle Extra-nuclear estrogen signaling RHOB GTPase cycle RHOC GTPase cycle CDC42 GTPase cycle RAC1 GTPase cycle RAC2 GTPase cycle RHOD GTPase cycle RHOQ GTPase cycle RHOH GTPase cycle RHOG GTPase cycle RHOJ GTPase cycle RAC3 GTPase cycle RHOF GTPase cycle FOXO-mediated transcription of cell cycle genes RND3 GTPase cycle RND2 GTPase cycle RND1 GTPase cycle SARS-CoV-1 targets host intracellular signalling and regulatory pathways SARS-CoV-2 targets host intracellular signalling and regulatory pathways Response of EIF2AK4 (GCN2) to amino acid deficiency Toll Like Receptor 5 (TLR5) Cascade Assembly of the SARS-CoV-2 Replication-Transcription Complex (RTC) SARS-CoV-2 Genome Replication and Transcription Transcription of SARS-CoV-2 sgRNAs Replication of the SARS-CoV-2 genome PI3K/AKT Signaling in Cancer PTEN Loss of Function in Cancer

Diagnóstico

Os sinais que médicos procuram e os exames que confirmam

Carregando...

Tratamento e manejo

Remédios, cuidados de apoio e o que precisa acompanhar

Pipeline de tratamentos
Pipeline regulatório — de medicamentos já aprovados a drogas em pesquisa exploratória.
3Fase 33
2Fase 28
1Fase 12
·Pré-clínico7
Medicamentos catalogadosEnsaios clínicos· 0 medicamentos · 20 ensaios
Carregando informações de tratamento...

Onde tratar no SUS

Hospitais de referência no Brasil e o protocolo oficial do SUS (PCDT)

🇧🇷 Atendimento SUS — Hipertensão arterial pulmonar hereditária

🗺️

Selecione um estado ou use sua localização para ver resultados.

Dados de DATASUS/CNES, SBGM, ABNeuro e Ministério da Saúde. Sempre confirme a disponibilidade diretamente com o estabelecimento.

Pesquisa ativa

Ensaios clínicos abertos e novidades científicas recentes

🟢 Recrutando agora

15 pesquisas recrutando participantes. Converse com seu médico sobre a possibilidade de participar.

Outros ensaios clínicos

829 ensaios clínicos encontrados, 29 ativos.

Distribuição por fase
Ver todos no ClinicalTrials.gov
🧪 Está conduzindo uma pesquisa?
Divulgue para pacientes e familiares que acompanham esta doença.
Divulgar pesquisa →

Publicações mais relevantes

Timeline de publicações
128 papers (10 anos)
#1

ANCA-associated vasculitis following sotatercept initiation in a patient with heritable pulmonary arterial hypertension and previously silent eosinophilic granulomatosis with polyangiitis: a case report.

European heart journal. Case reports2026 Feb

Pulmonary arterial hypertension (PAH) is a progressive disease characterized by increased pulmonary vascular resistance and right ventricular failure. Sotatercept, a novel activin receptor ligand trap, has demonstrated promising haemodynamic benefits in PAH treatment. Eosinophilic granulomatosis with polyangiitis (EGPA) is an extremely rare, Th2-driven, small-vessel vasculitis, and its overlap with PAH is scarcely reported. We report the case of a woman with heritable PAH initially stabilized with oral therapy. In 2024, after further clinical decline, subcutaneous treprostinil was initiated. Subsequently, sotatercept was added, resulting in brief clinical improvement. Within weeks, however, the patient developed severe eosinophilia and exhibited laboratory and histopathological evidence of p-ANCA-positive necrotizing vasculitis, accompanied by renal and hepatocellular dysfunction. This case suggests that sotatercept's modulation of the TGF-β pathway may unmask latent autoimmune diseases such as EGPA in predisposed individuals. Although the temporal relationship between sotatercept initiation and the onset of vasculitis is compelling, both causality and underlying molecular mechanisms remain to be elucidated. Further studies are necessary to understand the potential immunomodulatory mechanisms of sotatercept.

#2

Generation of 5 hiPSC lines from pediatric patients with Heritable pulmonary arterial hypertension (HPAH) caused by heterozygous mutations in the TBX4 gene.

Stem cell research2026 Feb

Heritable pulmonary arterial hypertension (HPAH) and underlying pulmonary vascular disease (PVD) are often caused by TBX4 mutations-either loss- or gain-of-function-which are a leading cause of childhood-onset PAH. The clinically heterogeneous TBX4 syndrome can include skeletal anomalies (e.g., small patella syndrome) and developmental lung disease (DEVLD) (Galambos, 2019). TBX4 is expressed in lung mesenchymal cells such as matrix fibroblasts, pericytes, and smooth muscle cells, all contributing to PAH pathogenesis (Karolak, 2023; Maldonado, 2025). Our five patient-derived TBX4-mutant hiPSC lines provide a powerful model to investigate cell-specific mechanisms in HPAH/DEVLD-PH and support precision drug discovery and therapy development targeting TBX4-related abnormalities.

#3

BMPR2 Splice-Site Variant in a Patient With Pulmonary Arteriovenous Malformation and Delayed-Onset Pulmonary Arterial Hypertension: A Case Report and Mechanistic Phenocopy Hypothesis.

American journal of medical genetics. Part A2026 Mar 08

Pulmonary arteriovenous malformations (PAVMs) are rare vascular anomalies most commonly seen in hereditary hemorrhagic telangiectasia (HHT), a condition associated with mutations in ENG, ACVRL1, SMAD4, or GDF2. In contrast, BMPR2 variants are well-established in heritable pulmonary arterial hypertension (PAH), but their relationship to PAVMs remains poorly understood. We report the case of a 41-year-old woman with an incidentally discovered PAVM, initially treated with embolization and subsequent surgical resection. She remained asymptomatic for several years until progressive exertional dyspnea led to a diagnosis of severe precapillary PAH. Genetic testing identified a heterozygous BMPR2 splice-site variant (c.967 + 5G>A), previously reported in a PAH cohort but currently classified as a variant of uncertain significance. This report is notable for the delayed evolution from isolated PAVM to PAH in the context of a BMPR2 variant, raising the possibility of a mechanistic link outside the canonical HHT pathway. We review published reports of BMPR2-associated PAVMs, some of which include subtle HHT-like features, such as mucocutaneous telangiectases and epistaxis, despite negative testing for classical HHT genes. These observations suggest a potential phenocopy vascular syndrome driven by disruption of the shared bone morphogenetic protein 9 (BMP9)-ALK1 signaling axis. We also discuss the implications of sotatercept, a transforming growth factor-beta (TGF-β) superfamily ligand trap, which in this case was associated with symptomatic improvement and stable shunt burden. These findings contribute to the emerging recognition of atypical vascular phenotypes in BMPR2 variant carriers, particularly those presenting with PAVMs in the absence of HHT. It highlights the importance of considering genetic testing in isolated AVM presentations, as well as the need for longitudinal surveillance and mechanistic investigation into overlapping TGF-β/BMP signaling disorders.

#4

A Large Animal Model of Heritable Pulmonary Arterial Hypertension Using Gene-edited BMPR2 Sheep.

bioRxiv : the preprint server for biology2026 Feb 07

Pulmonary Arterial Hypertension (PAH) is a rare vascular disorder characterized by elevated pressure in pulmonary arteries, eventually leading to right ventricular failure. Approximately 50% of pediatric disease and 20% of adult disease can be linked to a genetic mutation, with nearly 70% of these cases involving mutations in the bone morphogenetic protein receptor type 2 (BMPR2) locus. Investigations using rodent models have made significant advances in our understanding of BMPR2 signaling; however, limited data exist regarding the onset and course of PAH, and etiologies for phenotypic expression in these patients remain unknown. In this work, we describe the development of a novel ovine model of heritable PAH. Because homozygous disruption of BMPR2 is embryonic lethal, we developed heterozygous BMPR2 sheep by using a PAM-disrupting synonymous single stranded oligodeoxyribonucleotide alongside a single guide RNA and Cas9 mediated gene editing strategy. The resulting BMPR2 (+/-) lambs demonstrated cardiac and pulmonary vascular pathology that are consistent with BMPR2 mutation-driven PAH observed in humans. Given the genetic and physiological similarities of BMPR2 (+/-) sheep to humans with heritable PAH, this large animal model will serve as a vital platform for mechanistic molecular studies and will provide a much-needed pre-clinical model for extensive treatment evaluations.

#5

Heritable pulmonary arterial hypertension: new genetic findings and environmental triggers.

Scientific reports2026 Jan 29

Our goal was to identify new environmental or genetic causes in heritable pulmonary arterial hypertension (HPAH) families outside the 18 known diagnostics PAH genes. PAH gene panel sequencing was performed for 47 HPAH families which revealed pathogenic variants in 39 families. Five of the remaining families agreed to whole exome sequencing and to fill in a drug and toxin exposure questionnaire. In Family 1 and 2, mother and daughter with HPAH carried a likely pathogenic variant in the CYBA gene and a variant of uncertain significance in the FKBP1A gene, respectively, following ACMG guidelines. In Family 3, we detected a likely pathogenic variant in the PTGR2 gene. These genes could play part in PAH pathogenesis but further functional analyses are required to corroborate these findings. In the remaining two families, we could not identify any plausible genetic cause. However, a father and son with PAH reported exposure to trichloroethylene, asbestos and tramadol in Family 4. In Family 5, two brothers with pulmonary veno-occlusive disease showed occupational toxin exposure. Thus, our findings indicate that not only a genetic predisposition but also environmental triggers should be investigated for HPAH patients.

Publicações recentes

Ver todas no PubMed

📚 EuropePMC78 artigos no totalmostrando 126

2026

BMPR2 Splice-Site Variant in a Patient With Pulmonary Arteriovenous Malformation and Delayed-Onset Pulmonary Arterial Hypertension: A Case Report and Mechanistic Phenocopy Hypothesis.

American journal of medical genetics. Part A
2026

A Large Animal Model of Heritable Pulmonary Arterial Hypertension Using Gene-edited BMPR2 Sheep.

bioRxiv : the preprint server for biology
2026

ANCA-associated vasculitis following sotatercept initiation in a patient with heritable pulmonary arterial hypertension and previously silent eosinophilic granulomatosis with polyangiitis: a case report.

European heart journal. Case reports
2026

Heritable pulmonary arterial hypertension: new genetic findings and environmental triggers.

Scientific reports
2026

Generation of 5 hiPSC lines from pediatric patients with Heritable pulmonary arterial hypertension (HPAH) caused by heterozygous mutations in the TBX4 gene.

Stem cell research
2025

Unmasking Cancer Risk in Heritable PAH: The Hidden Role of BMPR2 in Epithelial Tumorigenesis.

JACC. Case reports
2025

Challenges in accurately assessing acute vasoreactivity in paediatric pulmonary arterial hypertension: case reports highlighting the impact of sedation on diagnostic accuracy.

European heart journal. Case reports
2025

A 2-Decade Cardiac Magnetic Resonance Imaging Journey in Heritable Pulmonary Arterial Hypertension: Reversal With Sotatercept.

JACC. Case reports
2026

Macitentan in Children with Pulmonary Arterial Hypertension: A Multicenter Experience.

Pediatric cardiology
2025

The genetic epidemiology and genotype-phenotype correlations among Chinese children with idiopathic and heritable pulmonary arterial hypertension.

Respiratory research
2025

Reduced pulmonary arterial compliance predicts poor short-term outcome in children with pulmonary arterial hypertension independent of pulmonary vascular resistance.

Frontiers in cardiovascular medicine
2025

Navigating family dynamics and ethical considerations in genetic diagnosis of pulmonary arterial hypertension: insights from in-depth semi-structured interviews.

ERJ open research
2025

Haemodynamic spectrum in heritable pulmonary arterial hypertension: a continuum from pre-capillary to combined pulmonary hypertension-case series.

European heart journal. Case reports
2025

Consistent Safety and Efficacy of Sotatercept for Pulmonary Arterial Hypertension in BMPR2 Mutation Carriers and Noncarriers: A Planned Analysis of a Phase II, Double-Blind, Placebo-controlled Clinical Trial (PULSAR).

American journal of respiratory and critical care medicine
2025

Ineffectiveness of Sotatercept Therapy in a Patient With Heritable Pulmonary Arterial Hypertension Associated With a Previously Unreported Missense Variant in GDF2, the Gene for Bone Morphogenic Protein-9.

Chest
2025

Sex-Specific Genetic Determinants of Right Ventricular Structure and Function.

American journal of respiratory and critical care medicine
2024

Deep phenotyping of unaffected carriers of pathogenic BMPR2 variants screened for pulmonary arterial hypertension.

The European respiratory journal
2024

Pulmonary Hypertension Induced by Right Pulmonary Artery Occlusion: Hemodynamic Consequences of Bmpr2 Mutation.

Journal of the American Heart Association
2024

[Heritable pulmonary arterial hypertension].

Innere Medizin (Heidelberg, Germany)
2024

Early identification of SOX17 deficiency in infants to guide management of heritable pulmonary arterial hypertension using PDA stent to create reverse Potts shunt physiology.

Pulmonary circulation
2024

Coexistence of pulmonary arterial hypertension and straight back syndrome in a patient with a novel BMPR2 variant affecting cytoplasmic tail domain.

European journal of medical research
2024

Heritable Pulmonary Arterial Hypertension in a Patient With Empty Sella Syndrome: A Case Report.

Cureus
2024

Heritable pulmonary arterial hypertension in rats with spontaneous systemic hypertension.

Revista espanola de cardiologia (English ed.)
2024

Hemodynamic and Clinical Profiles of Pulmonary Arterial Hypertension Patients with GDF2 and BMPR2 Variants.

International journal of molecular sciences
2024

BMPR2 mutation and clinical response to imatinib in a case of heritable pulmonary arterial hypertension.

Pulmonary circulation
2023

Long Term Survival of Heritable Pulmonary Arterial Hypertension Associated with Hereditary Hemorrhagic Telangiectasia: A Case Series.

Journal of clinical medicine
2024

Computed tomographic findings in TBX4 mutation: a common cause of severe pulmonary artery hypertension in children.

Pediatric radiology
2024

[A case of heritable pulmonary arterial hypertension treated with long-term oral low-dose imatinib].

Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases
2023

Pulmonary hypertension associated with diazoxide: the SUR1 paradox.

ERJ open research
2024

Treprostinil Effectiveness in Higher-Risk Pediatric Patients With Idiopathic and Heritable Pulmonary Arterial Hypertension.

The Canadian journal of cardiology
2023

Heritable Pulmonary Arterial Hypertension Diagnosed during the Postpartum Period: A Case Report and Literature Review.

Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir
2023

The cascade screening in heritable forms of pulmonary arterial hypertension.

Pulmonary circulation
2023

Is iron deficiency caused by BMPR2 mutations or dysfunction in pulmonary arterial hypertension patients?

Pulmonary circulation
2023

Differential biventricular adaption to pulmonary vascular disease in patients with idiopathic/heritable and congenital heart disease: a prospective cardiac magnetic resonance and invasive study.

European heart journal. Cardiovascular Imaging
2023

Prognostic Value for Mortality of Plasma Bioactive Adrenomedullin in Patients with Pulmonary Arterial Hypertension: A Sub Analysis of the Biomarker Study in the COHARD-PH Registry.

Medicina (Kaunas, Lithuania)
2023

Isolated Pulmonary Arteriovenous Malformations Associated With BMPR2 Pathogenic Variants.

Chest
2023

A cluster of heritable pulmonary arterial hypertension cases in a family with all three siblings carrying the same novel AQP1 c.273C>G variant-a case report.

Pulmonary circulation
2023

Clinical phenotyping of plasma thrombospondin-2 reveals relationship to right ventricular structure and function in pulmonary hypertension.

ERJ open research
2022

Higher circulating Trimethylamine N-oxide levels are associated with worse severity and prognosis in pulmonary hypertension: a cohort study.

Respiratory research
2023

Clinical differences between children and adults with idiopathic and heritable pulmonary arterial hypertension.

Cardiology in the young
2022

A pilot study to examine association of BMI with functional class and 6 min walk distance in idiopathic and heritable PAH: Possible association with estrogen metabolism.

Pulmonary circulation
2022

Safety of chronic high-dose calcium channel blockers exposure in children with pulmonary arterial hypertension.

Frontiers in cardiovascular medicine
2022

Reversible Cardiac Hypertrophy in Pulmonary Arterial Hypertension Treated With High-Dose Epoprostenol.

CJC open
2022

Clinical Implications of the Genetic Background in Pediatric Pulmonary Arterial Hypertension: Data from the Spanish REHIPED Registry.

International journal of molecular sciences
2022

Caveolin-1 associated with severe (pediatric-onset) presentation of pulmonary arterial hypertension.

Pulmonary circulation
2022

Whole Exome Sequencing of Patients With Heritable and Idiopathic Pulmonary Arterial Hypertension in Central Taiwan.

Frontiers in cardiovascular medicine
2022

Prognostic impact of follow-up pulmonary vascular resistance in pulmonary arterial hypertension.

Open heart
2022

Reduction of BMPR2 mRNA Expression in Peripheral Blood of Pulmonary Arterial Hypertension Patients: A Marker for Disease Severity?

Genes
2022

Prospective clinical assessment of patients with pulmonary arterial hypertension switched from bosentan to macitentan (POTENT).

Pulmonary circulation
2022

An adult case of NOTCH3 mutation in pulmonary artery hypertension.

Pulmonary circulation
2023

Clinical efficacy and safety of selexipag in children and young adults with idiopathic and heritable pulmonary arterial hypertension.

Cardiology in the young
2022

Pulmonary arterial hypertension in hereditary hemorrhagic telangiectasia associated with ACVRL1 mutation: a case report.

Journal of medical case reports
2022

Pediatric pulmonary veno-occlusive disease associated with a novel BMPR2 variant.

Pediatric pulmonology
2021

Gene Mutation Annotation and Pedigree for Pulmonary Arterial Hypertension Patients in Han Chinese Patients.

Global heart
2021

Hemodynamic and prognostic impact of the diastolic pulmonary arterial pressure in children with pulmonary arterial hypertension-a registry-based analysis.

Cardiovascular diagnosis and therapy
2021

<Editors' Choice> Differential effects of combination therapy on the components of the risk stratification table in patients with idiopathic or heritable pulmonary arterial hypertension in a Japanese population.

Nagoya journal of medical science
2021

Sex Dimorphism in Pulmonary Hypertension: The Role of the Sex Chromosomes.

Antioxidants (Basel, Switzerland)
2021

Supplementation with Iron in Pulmonary Arterial Hypertension. Two Randomized Crossover Trials.

Annals of the American Thoracic Society
2021

Heritable pulmonary arterial hypertension complicated by multiple pulmonary arteriovenous malformations.

Respiratory medicine case reports
2021

Screening for pulmonary arterial hypertension in adults carrying a BMPR2 mutation.

The European respiratory journal
2021

Plasma levels of apelin are reduced in patients with liver fibrosis and cirrhosis but are not correlated with circulating levels of bone morphogenetic protein 9 and 10.

Peptides
2020

Expression Quantitative Trait Locus Mapping in Pulmonary Arterial Hypertension.

Genes
2020

BMPR2 Promoter Variants Effect Gene Expression in Pulmonary Arterial Hypertension Patients.

Genes
2020

Expression of a Human Caveolin-1 Mutation in Mice Drives Inflammatory and Metabolic Defect-Associated Pulmonary Arterial Hypertension.

Frontiers in medicine
2020

PHorecasting Heritable Pulmonary Arterial Hypertension: Are We Nearly There Yet?

American journal of respiratory and critical care medicine
2021

Targeting transforming growth factor-β receptors in pulmonary hypertension.

The European respiratory journal
2020

A novel BMPR2 mutation in a patient with heritable pulmonary arterial hypertension and suspected hereditary hemorrhagic telangiectasia: A case report.

Medicine
2020

Knockdown of bone morphogenetic protein type II receptor leads to decreased aquaporin 1 expression and function in human pulmonary microvascular endothelial cells.

Canadian journal of physiology and pharmacology
2020

A novel BMPR2 mutation with widely disparate heritable pulmonary arterial hypertension clinical phenotype.

Pulmonary circulation
2020

Hereditary haemorrhagic telangiectasia with heritable pulmonary arterial hypertension.

European heart journal
2020

Whole-Blood RNA Profiles Associated with Pulmonary Arterial Hypertension and Clinical Outcome.

American journal of respiratory and critical care medicine
2020

Genetics of pulmonary hypertension and high-altitude pulmonary edema.

Journal of applied physiology (Bethesda, Md. : 1985)
2020

Clinical efficacy and safety of switch from bosentan to macitentan in children and young adults with pulmonary arterial hypertension: extended study results.

Cardiology in the young
2020

4PBA Restores Signaling of a Cysteine-substituted Mutant BMPR2 Receptor Found in Patients with Pulmonary Arterial Hypertension.

American journal of respiratory cell and molecular biology
2019

Genotypes and Phenotypes of Chinese Pediatric Patients With Idiopathic and Heritable Pulmonary Arterial Hypertension-A Single-Center Study.

The Canadian journal of cardiology
2019

Genetic linkage analysis of a large family identifies FIGN as a candidate modulator of reduced penetrance in heritable pulmonary arterial hypertension.

Journal of medical genetics
2019

A Combined Targeted and Whole Exome Sequencing Approach Identified Novel Candidate Genes Involved in Heritable Pulmonary Arterial Hypertension.

Scientific reports
2019

Idiopathic, heritable and veno-occlusive pulmonary arterial hypertension in childhood: computed tomography angiography features in the initial assessment of the disease.

Pediatric radiology
2019

A pediatric case of Ortner`s syndrome caused by heritable pulmonary arterial hypertension and review of the literature.

The Turkish journal of pediatrics
2019

Bmpr2 Mutant Rats Develop Pulmonary and Cardiac Characteristics of Pulmonary Arterial Hypertension.

Circulation
2019

Characterization and regulation of wild-type and mutant TASK-1 two pore domain potassium channels indicated in pulmonary arterial hypertension.

The Journal of physiology
2018

Pulmonary Arterial Hypertension and Hereditary Haemorrhagic Telangiectasia.

International journal of molecular sciences
2019

Clinical Effects of Syncope on Disease Severity and Adverse Outcomes in Children with Idiopathic and Heritable Pulmonary Arterial Hypertension.

Pediatric cardiology
2018

Factors Associated with Heritable Pulmonary Arterial Hypertension Exert Convergent Actions on the miR-130/301-Vascular Matrix Feedback Loop.

International journal of molecular sciences
2018

Clinical phenotypes and outcomes of pulmonary hypertension due to left heart disease: Role of the pre-capillary component.

PloS one
2018

Identification of rare sequence variation underlying heritable pulmonary arterial hypertension.

Nature communications
2018

Clinical prediction score for identifying patients with pulmonary veno-occlusive disease/pulmonary capillary hemangiomatosis.

Journal of cardiology
2018

Hypoxemia in patients with idiopathic or heritable pulmonary arterial hypertension.

PloS one
2017

Bilaterally dilated episcleral vessels in patients with heritable pulmonary arterial hypertension.

Journal of general and family medicine
2018

Clinical efficacy and safety of switch from bosentan to macitentan in children and young adults with pulmonary arterial hypertension.

Cardiology in the young
2017

Pulmonary Veno-Occlusive Disease: Welcome to the PAHty (Bostonian for Party).

Circulation
2018

Clinical Impact of Main Pulmonary Artery Dilatation on Outcome in Pediatric Idiopathic and Heritable Pulmonary Arterial Hypertension.

Circulation journal : official journal of the Japanese Circulation Society
2017

Heritable pulmonary hypertension: from bench to bedside.

European respiratory review : an official journal of the European Respiratory Society
2017

Pulmonary Hypertension in a Large Cohort with Hereditary Hemorrhagic Telangiectasia.

Respiration; international review of thoracic diseases
2017

Genetics of pulmonary hypertension in the clinic.

Current opinion in pulmonary medicine
2017

Left main coronary artery compression by a dilated main pulmonary artery and left coronary sinus of Valsalva aneurysm in a patient with heritable pulmonary arterial hypertension and FLNA mutation.

Pulmonary circulation
2017

Plasma proteome analysis in patients with pulmonary arterial hypertension: an observational cohort study.

The Lancet. Respiratory medicine
2017

Aberrant caveolin-1-mediated Smad signaling and proliferation identified by analysis of adenine 474 deletion mutation (c.474delA) in patient fibroblasts: a new perspective on the mechanism of pulmonary hypertension.

Molecular biology of the cell
2017

Improvement of pulmonary arterial hypertension following medication and shunt closure in a BMPR2 mutation carrier with atrial septal defect.

Journal of cardiology cases
2017

Pulmonary arterial capacitance index is a strong predictor for adverse outcome in children with idiopathic and heritable pulmonary arterial hypertension: methodological issues to avoid misinterpretation.

The Journal of pediatrics
2017

Aberrant Caveolin-1-Mediated Smad Signaling and Proliferation Identified by Analysis of Adenine 474 Deletion Mutation (c.474delA) in Patient Fibroblasts: A New Perspective in the Mechanism of Pulmonary Hypertension.

Molecular biology of the cell
2017

Tadalafil in idiopathic or heritable pulmonary arterial hypertension (PAH) compared to PAH associated with connective tissue disease.

International journal of cardiology
2017

Survival of Japanese Patients With Idiopathic/Heritable Pulmonary Arterial Hypertension.

The American journal of cardiology
2017

First identification of Krüppel-like factor 2 mutation in heritable pulmonary arterial hypertension.

Clinical science (London, England : 1979)
2017

Hypermethylation of BMPR2 Promoter Occurs in Patients with Heritable Pulmonary Arterial Hypertension and Inhibits BMPR2 Expression.

American journal of respiratory and critical care medicine
2017

Pulmonary hypertension and ventilation during exercise: Role of the pre-capillary component.

The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation
2016

Genotype-phenotype effects of Bmpr2 mutations on disease severity in mouse models of pulmonary hypertension.

Pulmonary circulation
2017

TNFα drives pulmonary arterial hypertension by suppressing the BMP type-II receptor and altering NOTCH signalling.

Nature communications
2017

EIF2AK4 Mutations in Patients Diagnosed With Pulmonary Arterial Hypertension.

Chest
2016

BMPRII influences the response of pulmonary microvascular endothelial cells to inflammatory mediators.

Pflugers Archiv : European journal of physiology
2017

Pulmonary Arterial Capacitance Index Is a Strong Predictor for Adverse Outcome in Children with Idiopathic and Heritable Pulmonary Arterial Hypertension.

The Journal of pediatrics
2016

Safety, Tolerability and Clinical Effects of a Rapid Dose Titration of Subcutaneous Treprostinil Therapy in Pulmonary Arterial Hypertension: A Prospective Multi-Centre Trial.

Respiration; international review of thoracic diseases
2017

Induced Pluripotent Stem Cell Model of Pulmonary Arterial Hypertension Reveals Novel Gene Expression and Patient Specificity.

American journal of respiratory and critical care medicine
2016

Pregnancy as a possible trigger for heritable pulmonary arterial hypertension.

Pulmonary circulation
2017

From bone morphogenic protein receptor II mutations to heritable pulmonary arterial hypertension-the long and winding road.

The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation
2016

Elevated levels of plasma transforming growth factor-β1 in idiopathic and heritable pulmonary arterial hypertension.

International journal of cardiology
2016

Mechanisms of Lipid Accumulation in the Bone Morphogenetic Protein Receptor Type 2 Mutant Right Ventricle.

American journal of respiratory and critical care medicine
2016

Rapid and high-dose titration of epoprostenol improves pulmonary hemodynamics and clinical outcomes in patients with idiopathic and heritable pulmonary arterial hypertension.

Journal of cardiology
2016

Elevated Levels of Circulating Bone Morphogenetic Protein 7 Predict Mortality in Pulmonary Arterial Hypertension.

Chest
2016

Critical Genomic Networks and Vasoreactive Variants in Idiopathic Pulmonary Arterial Hypertension.

American journal of respiratory and critical care medicine
2016

Potassium Channel Subfamily K Member 3 (KCNK3) Contributes to the Development of Pulmonary Arterial Hypertension.

Circulation
2016

Serotonin 2B Receptor Antagonism Prevents Heritable Pulmonary Arterial Hypertension.

PloS one
2015

Bone morphogenetic protein receptor type II deficiency and increased inflammatory cytokine production. A gateway to pulmonary arterial hypertension.

American journal of respiratory and critical care medicine
2015

Combining bosentan and sildenafil in pulmonary arterial hypertension patients failing monotherapy: real-world insights.

The European respiratory journal
2015

De novo mutations in the BMPR2 gene in patients with heritable pulmonary arterial hypertension.

Annals of human genetics
2015

Cardiac catheterization in children with pulmonary hypertensive vascular disease.

Pediatric cardiology

Associações

Organizações que acompanham esta doença — pra ter apoio e orientação

Ainda não temos associações cadastradas para Hipertensão arterial pulmonar hereditária.

É de uma associação que acompanha esta doença? Fale com a gente →

Comunidades

Grupos ativos de quem convive com esta doença aqui no Raras

Ainda não existe comunidade no Raras para Hipertensão arterial pulmonar hereditária

Pacientes, familiares e cuidadores se organizam em comunidades pra compartilhar experiências, fazer perguntas e se apoiar. Você pode ser o primeiro.

Tire suas dúvidas

Perguntas, dicas e experiências compartilhadas aqui na página

Participe da discussão

Faça login para postar dúvidas, compartilhar experiências e interagir com especialistas.

Fazer login

Doenças relacionadas

Doenças com sintomas parecidos — ajudam quem ainda está buscando diagnóstico

Referências e fontes

Bases de dados externas citadas neste artigo

Publicações científicas

Artigos indexados no PubMed ligados a esta doença no grafo RarasNet — título, periódico e PMID direto da fonte, sem intermediação de IA.

  1. ANCA-associated vasculitis following sotatercept initiation in a patient with heritable pulmonary arterial hypertension and previously silent eosinophilic granulomatosis with polyangiitis: a case report.
    European heart journal. Case reports· 2026· PMID 41669318mais citado
  2. Generation of 5 hiPSC lines from pediatric patients with Heritable pulmonary arterial hypertension (HPAH) caused by heterozygous mutations in the TBX4 gene.
    Stem cell research· 2026· PMID 41406515mais citado
  3. BMPR2 Splice-Site Variant in a Patient With Pulmonary Arteriovenous Malformation and Delayed-Onset Pulmonary Arterial Hypertension: A Case Report and&#xa0;Mechanistic Phenocopy Hypothesis.
    American journal of medical genetics. Part A· 2026· PMID 41795626mais citado
  4. A Large Animal Model of Heritable Pulmonary Arterial Hypertension Using Gene-edited BMPR2 Sheep.
    bioRxiv : the preprint server for biology· 2026· PMID 41676498mais citado
  5. Heritable pulmonary arterial hypertension: new genetic findings and environmental triggers.
    Scientific reports· 2026· PMID 41611798mais citado
  6. Heritable Pulmonary Arterial Hypertension Overview.
    · 1993· PMID 20301658recente
  7. Clinical Utility of Stroke Volume Index in Children with Idiopathic and Heritable Pulmonary Arterial Hypertension.
    Pediatr Cardiol· 2026· PMID 41925853recente

Bases de dados e fontes oficiais

Identificadores e referências canônicas usadas para montar este verbete.

  1. ORPHA:275777(Orphanet)
  2. MONDO:0017148(MONDO)
  3. Hipertensao Arterial Pulmonar(PCDT · Ministério da Saúde)
  4. GARD:11914(GARD (NIH))
  5. Variantes catalogadas(ClinVar)
  6. Busca completa no PubMed(PubMed)
  7. Q55786871(Wikidata)

Dados compilados pelo RarasNet a partir de fontes abertas (Orphanet, OMIM, MONDO, PubMed/EuropePMC, ClinicalTrials.gov, DATASUS, PCDT/MS). Este conteúdo é informativo e não substitui avaliação médica.

Conteúdo mantido por Agente Raras · Médicos e pesquisadores podem colaborar

Hipertensão arterial pulmonar hereditária
Compêndio · Raras BR

Hipertensão arterial pulmonar hereditária

ORPHA:275777 · MONDO:0017148
🇧🇷 Brasil SUS
CEAF
1ABosentana1BAmbrisentanaSildenafilaIloprosta+3 mais
Internações
4.560/ano
Prevalência BR
15:1000000
Custo SUS
R$ 9.870/internação
Dados
DATASUS 2024
Geral
Prevalência
<1 / 1 000 000
Herança
Autosomal dominant, Autosomal recessive
CID-10
I27.0 · Hipertensão pulmonar primária
CID-11
Ensaios
29 ativos
Início
All ages
Prevalência
0.08 (Europe)
MedGen
UMLS
C0340543
Repurposing
141 candidatos
acebutololadrenergic receptor antagonist
alaceprilangiotensin converting enzyme inhibitor
aliskiren-hemifumaraterenin inhibitor
+17 outros
EuropePMC
Wikidata
Papers 10a
DiscussaoAtiva

Nenhuma novidade ainda. O agente esta monitorando.

0membros
0novidades